
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 18, 2016

AMEDICA CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-33624
(Commission
File Number)

84-1375299
(I.R.S. Employer
Identification No.)

1885 West 2100 South
Salt Lake City, Utah 84119
(Address of Principal Executive Offices)

Registrant's telephone number including area code: **(801) 839-3500**

N/A
(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Section 1 - Registrant's Business and Operations

Item 7.01. Regulation FD Disclosure.

On April 14, 2016 (the "**Effective Date**"), Amedica Corporation ("**Amedica**"), entered into a Distribution Agreement (the "**Agreement**") with Shandong Weigao Orthopedic Device Company Limited (the "**Weigao**"), to sell Amedica branded silicon nitride spinal interbody fusion devices ("**Products**") for exclusive resale by Weigao within the People's Republic of China (the "**Territory**"). Weigao has established facilities, trained personnel, customer service support and special expertise with respect to the resale of Products such as those manufactured by Amedica in the Territory.

Amedica shall be responsible, at its sole expense, to obtain Chinese Food and Drug Administration (the "**CFDA**") clearance to sell the products in China. It is expected such approval may require Amedica to conduct mechanical properties testing, biological compatibility testing, sterilization validation, dose confirmation testing, packing testing, zoology testing, physical properties testing, clinical testing, registration testing, and registration samples for the products. In connection with seeking such clearance Amedica will file all regulatory dossiers for Products in the Territory under its name and shall own all regulatory approvals with respect to these Products. Weigao has expertise in acquiring CFDA approval of medical devices in the Territory and shall utilize such expertise to assist Amedica in accelerating the obtainment of CFDA approval of Products in the Territory. Such assistance shall include advising on the filing for all regulatory dossiers and approvals for Products in the Territory, providing Amedica with a list of the documents required to be submitted to the CFDA in order to acquire CFDA approval to commercialize Products in the Territory; arrange for and manage the material testing of the Products; assist in the design and conduct of any required human clinical trials with the Products in the Territory and any required follow-up activities; and, assist in the preparation of the application for approval to be submitted to CFDA, such application to be submitted on behalf of Amedica.

Pursuant to the terms of the Agreement, once CFDA clearance is obtained, Weigao will be required to purchase at least the annual minimum number of Products specified below during the remaining term of the Agreement (each, an "**Annual Minimum**"). If Weigao fails to purchase its Annual Minimum in any one year then Weigao shall make up any shortfall in actual purchases for that year by either product purchases from Amedica in such quantities so as to satisfy the Annual Minimum or by paying Amedica an amount equal to the net profit Amedica would have made on such shortfall as if Weigao had purchased the full amount of the requirement, alternatively, Amedica will have the right, at its option, to terminate the Agreement. Weigao will submit a purchase order for an initial stocking order of Product within thirty days of CFDA approval of the Products for sale in the Territory.

Minimum purchase commitment of Products associated with exclusivity following CFDA approval:

Year 1	20,000 units
Year 2	35,000 units
Year 3	35,000 units
Year 4	40,000 units
Year 5	45,000 units
Year 6	50,000 units

The term of the Agreement will commence on the Effective Date and continue for a period of ten years from receipt of approval by the CFDA. Unless terminated in accordance with the terms of the Agreement, this Agreement may be renewed for additional one (1) year terms upon written and fully executed agreement between the Parties. Company may terminate this Agreement on thirty days written notice for any reason or no reason whatsoever before approval by the CFDA or after the initial ten year term expires.

Item 8.01. Other Events.

On April 18, 2016, Amedica Corporation issued a press release announcing that it has entered into a Distribution Agreement with Shandong Weigao Orthopedic Device Company Limited. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated April 18, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDICA CORPORATION

Dated: April 18, 2016

By: /s/ Ty Lombardi

Ty Lombardi
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release Dated April 18, 2016



Amedica Signs Exclusive Chinese Silicon Nitride Distribution Agreement

10-Year Exclusive Agreement to Represent Significant Global Sales Expansion and Minimum Purchase Requirements

SALT LAKE CITY, April 18, 2016 – Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce a partnership with Shandong Weigao Orthopedic Device Company Limited (“Weigao Orthopedic”), a subsidiary of Shandong Weigao Group Medical Polymer Company Limited (HKSE:1066), a medical device company in China specializing in the R&D, production and sale of spine, trauma and joint orthopedic implants.

Under the distribution agreement, Weigao Orthopedic will have exclusive rights for the sale, marketing and distribution of Amedica-branded silicon nitride spinal implants in the People’s Republic of China, and will abide by minimum annual purchase requirements in Year 1 of 20,000 units, growing annually to 50,000 units in Year 6, following regulatory clearance by the China Food and Drug Administration (CFDA). Weigao Orthopedic will leverage its expertise in acquiring CFDA clearance of medical devices, in order to accelerate Chinese clearance of Amedica’s products.

“With more than 50,000 minimum unit sales to occur within the first two years following CFDA clearance, this agreement far surpasses total silicon nitride unit sales to-date, and marks a momentous time for Amedica,” said Dr. Sonny Bal, Chairman and Chief Executive Officer. “This partnership with Weigao Orthopedic allows us to significantly increase our global sales footprint with a large-scale distribution partner who is familiar with the Chinese regulatory landscape. Weigao Orthopedic’s expertise in sales and distribution is an excellent fit for our innovative silicon nitride technology platform. We look forward to this key strategic partnership to distribute our silicon nitride technology into Asian markets that are particularly receptive to bioceramic implants.”

“We are very pleased with this exclusive distributor partnership as we plan to leverage the Amedica brand to offer a truly differentiated product to our broad network of hospitals and medical units in China,” stated Mr. Gong Jianbo, Chief Executive Officer and Executive Director of Weigao Orthopedic. “We expect the combination of this technically advanced biomaterial with our well-established network to quickly gain significant market share. We also look forward to expanding our partnership beyond spine products and into hip and knee applications. Weigao Orthopedic is well positioned to facilitate the approval and commercial launch of Amedica’s silicon nitride spinal fusion devices in one of the world’s largest healthcare markets.”

About Amedica Corporation

Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Shandong Weigao Group

Shandong Weigao Group and its subsidiaries are principally engaged in the research and development, production and sale of single-use medical devices. The Group has a wide range of products, which includes consumables, orthopedic materials, and blood purification consumables and equipment. The Group's main production facilities are situated in Weihai, Shandong Province.

The Group is incorporated in the People's Republic of China and has an extensive sales network comprising 28 sales offices, 34 customer liaison centers and 222 cities with sales representatives. Shandong Weigao Group has a total customer base of 5,298 (including 3,132 hospitals, 414 blood stations, 643 other medical units and 1,109 distributors).

For more information on Shandong Weigao Group, please visit <http://en.weigaogroup.com>.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica's future performance, business operations and acceptance of its technology platform. Statements relating to Amedica's expectation that the relationship with Weigao will expand the Company's global sales footprint and provide incremental growth for Amedica's unique biomaterial will be significantly expanded, that scientific results may result in innovative solutions, increased market opportunities, growth, future products, market acceptance of its products, sales and financial results and similar statements are subject to risks and uncertainties such as whether the Chinese FDA will clear the products for use in China, the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts:

Mike Houston
VP, Commercialization
801-839-3534
IR@amedica.com

Robert Haag
Managing Director
IRTH Communications
866-976-4784
amda@irthcommunications.com
